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Lipid peroxidation induced etheno-DNA adducts are promutagenic and have been suggested
to play a causal role in the development of human cancers. Therefore, human biomonitoring
of etheno-DNA adducts in urine has been suggested as a potential marker for oxidative
stress-related DNA damage. For quantitative determination, a column-switching LC/APCI-
MS/MS method was developed for simultaneous analysis of Ade, dC, and dA in human
urine. Quantitative validation parameters (precision, within-day repeatability, and between-
day reproducibility) yielded satisfactory results below 10%. Limit of quantification for Ade,
dC, and dA was 5.3 fmol, 7.5 fmol, and 1.3 fmol on column, respectively. Mean urinary
excretion rates of a six healthy volunteers were 45.8 pmol Ade/24 h, 96.8 pmol dC/24 h, and
18.1 pmol dA/24 h. The demonstrated levels of performance suggest a future applicability of
this method to studies of cancer and other diseases related to oxidative stress in humans. To
our knowledge, this is the first method described that allows simultaneous determination of
Ade, dC, and dA in human urine samples. (J Am Soc Mass Spectrom 2006, 17, 605–610)
© 2006 American Society for Mass SpectrometryEtheno modified DNA bases, such as dA, origi-nating from known human carcinogens vinylchloride [1] or ethyl carbamate [2], are also gen-
erated endogenously by reactions of DNA with prod-
ucts derived from lipid peroxidation and oxidative
stress [3]. These DNA adducts have miscoding potential
and specific repair pathways supporting the hypothesis
that -DNA adducts play a causal relationship in carci-
nogenesis [4]. Furthermore, several studies have found
elevated -DNA adduct levels in disorders known as
risk factors for cancers [5, 6]. Therefore -DNA adducts
have been proposed as biomarkers for human cancers
associated with certain lifestyles or chronic inflamma-
tions [4]. Upon DNA repair, -DNA adducts are ex-
creted in the urine and could, in that respect, be used to
investigate the body burden of DNA damage.
The analytical procedures for urinary DNA adducts
are challenging indeed. The presence of many interfer-
ing substances in concentrations far greater than those
of the DNA adducts demands high selectivity and low
limit of quantitation for unequivocal identification and
quantification. Methods using high-performance liquid
chromatography (HPLC) with fluorescence detection
have been used for dA determination [4, 7] after
immunoaffinity clean-up and a very tedious sample
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doi:10.1016/j.jasms.2005.12.012preparation. Furthermore, the internal standard was
measured separately. Several etheno-DNA adducts
have been determined in urine from healthy humans
using gas chromatography-electron capture negative
chemical ionization mass spectrometry (GC/EC-NCI/
MS) [8 –11]. Gas chromatography offers the advantage
of greater peak resolution compared to conventional
LC. However, the requirement for derivatization before
analysis is a major limitation. Recently, LC-MS have
been employed in determination of etheno adducts
from human urine using electrospray ionization (ESI)
[12–14]. Atmospheric pressure chemical ionization
(APCI) has been used for analysis of dA and 1,N2-dG
in vitro [15] and of dA in human urine [16].
In this paper, we report that solid-phase extraction
(SPE) for preconcentration combined with HPLC col-
umn switching tandem mass spectrometry can quantify
urinary etheno-DNA modifications. This approach
demonstrates progress in the simultaneous analysis of
urinary Ade, dC, and dA in terms of specific iden-
tification and the stringent sensitivity requirements
needed for low-level analysis.
Methods
Materials
Glacial acetic acid was from Merck KgaA (Darmstadt,
Germany) while methanol and 25% aqueous ammonia
were supplied from J. T. Baker (Deventer, The Nether-
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Gradient A10 system (Millipore, Bedford, MA). All
other solvents were of analytical grade. Lithium acetate
dihydrate was from Sigma-Aldrich Co. Ltd. (Steinheim,
Germany).
3,N4-etheno-2=-deoxycytidine (dC), 1,N6-ethenoadenine
(Ade), 1,N6-etheno-2=-deoxyadenosine (dA), and the
stable isotope-labeled equivalents [15N3]-dC, [
15N5]-
Ade, and [15N5]-dA used as internal standards (ISTD),
were all synthesized in our laboratory by the method of
Green and Hathway [17] with subsequent HPLC purifi-
cation. The isotopic purity was determined by LC-MS/
MS. No unlabeled adduct was present in the labeled
analog (0.01%). Absorption spectra of the standard and
the internal standard were also identical. Concentrations
were determined by measuring the UV-absorbance in
water (dC; 272 nm  12,000 M
1cm1 [18], Ade and
dA; 260 nm  10,300 M
1cm1 [17]).
Liquid Chromatography
The set-up is shown in Figure 1. The liquid handling
system consisted of two pumps. Pump 1: an Agilent
1100 binary HPLC pump (Agilent, Palo Alto, CA)
connected to a PE autosampler and Pump 2: a single PE
200micro pump (Perkin Elmer, Norwalk, CT).
The components for the two-dimensional separation
consisted of column 1 (C1), a Luna HPLC column C18(2)
(150 4.6 mm, 5 m) protected with a C18 (ODS) guard
column (4.0  3.0 mm); column 2 (C2) was a Synergi
Polar-RP column (75  4.6 mm, 4 m); column 3 (C3)
was a Synergi Polar-RP column (150  4.6 mm, 4 m).
All columns were from Phenomenex (Torrance, CA).
Constant column temperatures were achieved using an
Agilent 1100 Column Oven (Agilent, Palo Alto, CA) and
a Comfort Heto Chill Master (Holm and Halby,
Brøndby, Denmark), maintaining C1 at 40 °C and C2
and C3 at 1 °C. Pump 1 was connected to eluent A:5
mM ammonium acetate (pH 5), and eluent B:100%
methanol; Pump 2 was connected to eluent C:92.5% 5Figure 1. Schematic view of the analytical set-up.mM ammonium acetate in methanol (vol/vol). Column
switching was achieved using three Cheminert valves
(Valco International, Schenkon, Switzerland): Valve 1
(8-port 4-position two-stream selection C5F), Valve 2
(8-port 4-position C5F), and Valve 3 (6-port 2-position
C2), all fitted with micro-electric valve actuators.
Figure 1 (and Table in Supplementary Material sec-
tion which can be found in the electronic version of this
article.) show in detail the chromatographic conditions
for the developed method. The experiment was con-
ducted according to the following scheme: first, initial
separation on the primary column (C1) by Pump 1 and
re-equilibration of C2  C3 by Pump 2; second, loading
a heart-cut fraction containing Ade from C1 onto C2;
third, gradient elution of C2 into the MS by Pump 1 and
continued separation on C1 by Pump 2; fourth, sus-
tained gradient elution of C2 into the MS and at the
same time loading a heart-cut fraction containing dC
 dA from C1 onto C3; fifth, gradient elution of C3
into the MS by Pump 1 and re-equilibration of C2 by
Pump 2; and sixth, before injecting the next sample,
washing  re-equilibration of C1 by Pump 1. Three
valves accomplished the switching operations. Valve 1
was directing the gradient flow from Pump 1 through
the columns. Valve 2 was programmed to multiple
switches between waste and loading of the “heart-cut”
fractions. Valve 3 was directing the isocratic flow from
Pump 2 through the columns.
Mass Spectrometry
The mass spectrometer used was an API 3000 triple
quadrupole (Sciex, Toronto, Canada) equipped with an
APCI ion source (Heated Nebulizer). The vaporizer tem-
perature was 500 °C. Nitrogen was used as nebulizer-,
auxiliary-, and collision gas. Interface settings and gas
pressures were manually optimized at the LC conditions
prevailing when the analyte in question elutes into the
MS. Detections were performed in MRM mode. “High-
resolution mode” corresponding to a peak width of 0.5 u
at half the maximum peak height (0.5 FWHM) was used
in both the first quadrupole (Q1) and the third quadrupole
(Q3).
Sample Handling
Aliquots of 24-h urine samples were obtained from 6
nonsmoking healthy men (age 21–48 y) consuming
unrestricted diets, and stored at 20°C before analysis.
The urine was collected as part of another study esti-
mating oxidative stress from dietary intervention and
was approved by the local ethics committee of Copen-
hagen (no. 01-099102).
Solid-phase extraction was performed as described
previously with minor modifications [16]. The frozen
urine was thawed and 2 mL aliquots were diluted 1:2 in
5 mM ammonium acetate (pH 5) and heated to 37 °C for
5 min. ISTD were added to all samples, which were
loaded onto an Oasis HLB cartridge (Waters, Milford,
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conditioned with 3  1 mL of methanol and 3  1 mL
of H2O. Sample application was performed slowly
under gravity flow. The column was washed with 3.5
mL of water, followed by 2  750 L of 10% methanol
(aq) and subsequently dried under vacuum. The ana-
lytes were eluted with 2 950 L of 75% methanol (aq),
and the eluate was vacuum-centrifuged to dryness. The
residue was redissolved in 160 L of 0.5 M lithium
acetate buffer (pH 6.4), and sonicated. This was done to
redissolve precipitate-trapped adducts. An aliquot (75
L) of the solution was injected into the HPLC system
and dual post-injection flushes of the syringe with
eluent A were performed to prevent carryover from the
needle.
Validation Procedures
A validation program was executed according to the
FDA guidelines [19]. The challenge in designing the
validation protocol relates to the fact that no human
urine can be found without detectable endogenous
levels of the studied etheno adducts.
The linearity and range of the calibration curves
were established in a single series over the working
concentration range with nine levels of standards in
duplicates. The calibration curves are expressed as the
ratio between the areas of the analyte peak/the ISTD
peak as a function of the analyte concentration. Two
calibration curves that underwent the complete SPE
procedure were simultaneously prepared in water and
in urine. These were compared with a curve of directly
analyzed standards.
Reproducibility and recovery studies were per-
formed to compile method performance. The within-day
and between-day variances were estimated from three
series of six human urine samples in triplicate. The
urine samples were chosen to cover a broad diuresis
range (681–4500 mL/24 h). Precision is expressed as the
percentage of relative standard deviation (RSD, %). To
assess the effect of repeated freeze-thaw cycles on the
analytes, injections were performed on fresh extracted
aliquots. Then, the urine samples were refrozen and
reanalyzed twice over the next three weeks as part of
the reproducibility study. Recovery from SPE was de-
termined by duplicate analysis of synthetic samples
(water) and two urine samples from the reproducibility
study. The samples were spiked at two levels (Ade:
100 and 400 fmol; dC: 100 and 400 fmol, and dA: 15
and 40 fmol) and extracted as a normal sample. How-
ever, in this particular experiment, the addition of
internal standards to the spiked samples were first
executed at the redissolvation step and will, in that
respect, not compensate for any losses up till this point
in the recovery study. The ISTD will, however, correct
response variation originating from the ionization pro-
cess. The unspiked urine samples were included in the
set and their mean concentrations were used as blank
estimations. Recovery is expressed as the percentage ofrecovery [({Mean observed concentration  blank con-
centration}/{spiked concentration})  100%].
Statistical Analysis
All results are reported as the means  standard
deviation (SD). STATISTICA version 6.0 (StatSoft, Inc.,
Tulsa, OK) was used for these analyses.
Results and Discussion
The evidence accumulated to date suggests that etheno
adducts may be useful noninvasive biomarkers for lipid
peroxidation related DNA damage. Urine is a complex
matrix containing a mixture of multiple compounds in
concentrations far greater than those of the modified
adducts. As a consequence, interfering substances often
hinder the direct determination of the analytes. The
assays available, however, have required either exten-
sive cleanup steps or very specific immunoaffinity
columns. The methodology presented here consisted of
a simple enrichment step with SPE followed by column
switching HPLC and quantification by isotope dilution
tandem mass spectrometry.
The strategy of column-switching is clearly attractive
for the analysis of complex mixtures. It provides the
optimum efficiency and selectivity for separation of
compounds of interest, eliminating several sample
preparation steps necessary for single column ap-
proach. A critical parameter is the selection and trans-
ference of the heart-cut fraction from the primary col-
umn to the secondary column. Selection is achieved by
time-based valve switching assuming constant reten-
tion times. However, during a run the retention time
can drift as a consequence of column degradation or
pressure build-up. One way to overcome this problem
is to use an isotope-labeled internal standard, since the
analyte and the internal standard should behave in a
chromatographically identical way, the internal stan-
dard can be used to deal with this “drifting peak”
phenomenon because the calibration was based on area
ratios. Furthermore, isotope-labeled ISTD can be used
to compensate for losses during sample preparation
and to compensate for variation and suppression of
ionization. Because elution of the trapped compounds
into the MS should be accomplished with the smallest
possible solvent volume to maximize mass spectral
response, the heart-cut fraction needs to be focused in a
narrow band at the top of the secondary column.
Therefore, cold temperature (1 °C) focusing on the two
secondary columns (C2 and C3) was employed.
In complex samples, it is inevitable that some of the
interfering compounds will be transferred together
with the analytes of interest. By using two secondary
columns, this problem was minimized, which allows
final separation and subsequent MS detection of the
Ade containing fraction alone, while initial separation
of dC and dA from interfering peaks continues. This
strategy has the advantage of optimizing valuable MS
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Furthermore, it allows a steeper gradient on each of the
secondary columns and, consequently, sharper peaks
and better ionization attributable to the higher content
of organics in the final effluent composition.
To achieve high selectivity and S/N ratio, detection
was performed in MRM mode. The overall signal
sensitivity of Ade was highest in negative mode.
Furthermore, when analyzing real samples, the back-
ground noise was also lower in negative mode, mean-
ing that the sensitivity in terms of signal-to-noise was
much higher in negative mode than in positive mode.
For dC and dA, best sensitivity was obtained in
positive mode. Due to the low intensity of other frag-
ments from the collision-induced dissociation, and con-
sidering the low concentrations found in urine samples,
no qualifier ions for analyte verification could be in-
cluded in the final method.
During method development, two calibration curves
were simultaneously prepared; one in water and one in
urine to examine a possible influence of the urine
matrix on slope and linearity. These were compared
with a curve of directly analyzed standards. Urine
matrix and SPE procedure did not influence slope and
linearity of the calibration curve (data not shown;
however, calculated accuracy of the concentrations
were within 5%). Therefore, calibration graphs were
obtained directly by analyzing water standards without
sample processing. Linearity was assessed using nine
standard solutions in duplicates. Linear relationships
were obtained for all three adducts in the following
concentration range investigated: (LOQ-40.6 nM for
Ade, LOQ-4.0 nM for dC, and LOQ-4.0 nM for dA)
Figure 2. LC/APCI-MS/MS chromatograms o
two time windows. Time window 1 shows the 1
Ade. Time window 2 shows the 252/136 (ISTD
corresponding to dC and dA, respectively. The
and 8.9 pM dA.when a weighting factor of 1/x2 was used for allcompounds. LOQ based on an S/N of 5:1 was about 70
pM, 100 pM, and 17 pM in the final sample concentrate
for Ade, dC, and dA, respectively. This corre-
sponded to urine concentrations of 5.6 pM, 8.0 pM, and
1.4 pM for Ade, dC, and dA, respectively. The LOQ
for Ade was five times lower than reported by Chen
and Chang [12], 10 times lower for dC [11] and dA
[7], analyzing comparable urine volumes. Figure 2
presents representative chromatograms obtained for a
urine sample.
The analytical intra-day and inter-day precisions are
shown in Table 1. The coefficients of variation of the
reproducibility study were generally below 10% RSD.
These accuracy and precision determinations are com-
parable to those previously reported. Blank solvent
samples analyzed within the batch verified no car-
ryover from either urine samples or the highest stan-
dard sample. The recovery of the entire assay at both
fortification levels for standards and human urine were
in the range15% of nominal 100% recovery (86.7–97.3,
92.0–96.5, and 87.2–100.0% for Ade, dC, and dA,
respectively) and standard derivations not exceeding
10%. The etheno adducts are stable in human urine
throughout at least three freeze-thaw cycles. To assess
the effect of long-term (2 y at 20 °C) storage, one
urine sample was analyzed and data compared to the
dA concentration measured previously. The dA con-
centrations found were indistinguishable within
method variation.
The main problem encountered by LC-MS/MS anal-
ysis relates to matrix effects, in particular ion suppres-
sion. Due to high variations in matrix effects from
sample to sample and even analyte to analyte, one
al sample. Each chromatogram is divided into
17 (ISTD: 163/121) transitions corresponding to
/139) and 276/160 (ISTD: 281/165) transitions
e sample contained 32.0 pM Ade, 79.0 pM dC,f a re
58/1
: 255
urinneeds to address interindividual matrix effect. There-
609J Am Soc Mass Spectrom 2006, 17, 605–610 ETHENO-DNA ADDUCTS BY LC/APCI-MS/MSfore, it is important to evaluate matrix during method
validation by using different batches of urine. The urine
samples were chosen to cover a broad diuresis range.
The use of stable isotope-labeled internal standards,
which is expected to experience the same exact matrix
effect as the analyte, will not eliminate the matrix effect
but will ensure that the accuracy/precision of the
method is unaffected. However, the matrix effect could
significantly lower the response, affecting the achiev-
able detection limit. Various degrees of ion suppression
were observed by Chen and Chiu using ESI, the extent
of decreased signals ranging from one-third to one-
seventh [13]. APCI was chosen as the ionization mode
for MS detection since APCI ion intensities are not as
strongly affected by coeluting matrix constituents as in
electrospray ionization [20, 21]. The signal intensity of
the ISTD transitions was almost identical for a real
sample compared to a standard, indicating negligible
ion suppression, as identical amounts of ISTD has been
added to both samples and standards.
The concentrations of the etheno adducts in human
urine were: Ade, 34.9  29.0; dC, 60.8  33.8; dA,
11.9  8.7 pM (n  6). The corresponding levels of
urinary excretion rates in the six subjects were in the
ranges 14.2–117.3 pmol Ade/24 h, 53.2–117.8 pmol
dC/24 h, and 9.8–23.4 pmol dA/24 h. The basal
levels here are comparable with those of dA [7, 16] and
dC [11] found previously. Slightly higher excretion
levels of Ade than our finding have been reported by
Chen and coworkers [9, 12]. The discrepancies in these
findings are minor and may be attributable to experi-
mental variation and differences in population and
exposures. There was no relationship between excretion
rate of Ade and either of the nucleoside adducts;
however, although the samples numbers were limited,
there seemed to be a correlation between dC and dA
excretion.
Conclusions
In conclusion, this study is the first paper on simulta-
neous detection of the promutagenic etheno-adducts
Ade, dC, and dA in human urine. The column-
switching LC/APCI-MS/MS assay provides a useful








Urine A 1928 15.2 4.9 4.6
Urine B 2499 5.7 9.6 10.9
Urine C 4500 6.0 4.7 5.3
Urine D 1690 69.4 3.5 1.0
Urine E 859 55.0 2.0 2.0
Urine F 681 58.3 3.9 0.0
aRSD in %.tool for establishing determining factors and for inves-tigations of the relationship to disease, in particular
cancer development, and do not require radioactive
standards or very specific antibodies. The method is a
sensitive and reliable tool suitable for determination of
the urinary excretion of Ade, dC, and dA, even at
low levels, in humans. The method is validated with
respect to linearity, precision, and accuracy. The analy-
sis of real samples was demonstrated, and this assay
may be useful for large-scale studies.
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